title: Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and CISH-negative EGFR gene alterations.
abstract: BACKGROUND
  Epidermal growth factor receptor (EGFR) positivity as assessed by chromogenic in situ hybridization (CISH) has been demonstrated to be associated with EGFR mutation status. This study was conducted to compare the responsiveness of CISH-positive and CISH-negative lung adenocarcinomas to erlotinib.
  
  
  METHODS
  Patients received erlotinib (150 mg/day) alone until disease progression or intolerable toxicity. EGFR gene status was examined by CISH. The response rate (RR), progression-free survival (PFS), overall survival (OS) and toxicity profiles were assessed.
  
  
  RESULTS
  Thirty-one patients underwent response evaluations and CISH analyses, 12 of whom harboured CISH-positive adenocarcinomas. The overall RR (p=0.035), median PFS (p=0.091) and median OS (p=0.408) were higher in the CISH-positive group. No difference in toxicity profiles was observed between these two groups.
  
  
  CONCLUSIONS
  EGFR status as assessed by CISH can predict the response to erlotinib in patients with advanced lung adenocarcinoma.
authors.affiliation: Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, 5 Fu-Shin Street, Kwei-Shan, Taoyuan 333, Taiwan, R.O.C.
authors.forename: Ming-Mo
authors.initials: MM
authors.lastname: Hou
authors.forename: Shiu-Feng
authors.initials: SF
authors.lastname: Huang
authors.forename: Han-Pin
authors.initials: HP
authors.lastname: Kuo
authors.forename: Cheng-Ta
authors.initials: CT
authors.lastname: Yang
authors.forename: Ying-Huang
authors.initials: YH
authors.lastname: Tsai
authors.forename: Chih-Teng
authors.initials: CT
authors.lastname: Yu
authors.forename: Horng-Chyuan
authors.initials: HC
authors.lastname: Lin
authors.forename: Chih-Hung
authors.initials: CH
authors.lastname: Chen
authors.forename: Chih-Liang
authors.initials: CL
authors.lastname: Wang
authors.forename: Fu-Tsai
authors.initials: FT
authors.lastname: Chung
authors.forename: Jia-Juan
authors.initials: JJ
authors.lastname: Hsieh
authors.forename: Todd
authors.initials: T
authors.lastname: Hsu
authors.forename: Hsin-Yi
authors.initials: HY
authors.lastname: Cheng
authors.forename: Li-Ying
authors.initials: LY
authors.lastname: Ou
authors.forename: Hung-Ming
authors.initials: HM
authors.lastname: Wang
authors.forename: Yung-Chang
authors.initials: YC
authors.lastname: Lin
authors.forename: Nai-Jen
authors.initials: NJ
authors.lastname: Chang
authors.forename: John Wen-Cheng
authors.initials: JW
authors.lastname: Chang
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D017403:In Situ Hybridization / Q000379:methods*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000627:therapeutic use*; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors